China’s military has received the greenlight to use a COVID-19 vaccine candidate developed by its research unit and CanSino Biologics after clinical trials proved it was safe and showed some efficacy, the company said yesterday. The Ad5-nCoV is one of China’s eight vaccine candidates approved for human trials at home and abroad for Covid-19, Reuters reported. Ad5-nCoV was jointly developed by a team at the Academy of Military Medical Sciences, led by Major General Chen Wei, and Tianjin-based company CanSino Biologics, South China Morning Post (SCMP) reported today.
It is the first time that a vaccine candidate for Covid-19 has been authorized for use for the military of any nation. Yesterday, CanSino said the candidate had been through two phases of clinical trials, which indicated it was safe and there was “relatively high” immune response to the antigen.
